SG11202002982YA - Multispecific antibody - Google Patents
Multispecific antibodyInfo
- Publication number
- SG11202002982YA SG11202002982YA SG11202002982YA SG11202002982YA SG11202002982YA SG 11202002982Y A SG11202002982Y A SG 11202002982YA SG 11202002982Y A SG11202002982Y A SG 11202002982YA SG 11202002982Y A SG11202002982Y A SG 11202002982YA SG 11202002982Y A SG11202002982Y A SG 11202002982YA
- Authority
- SG
- Singapore
- Prior art keywords
- multispecific antibody
- multispecific
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17195779.8A EP3470426A1 (fr) | 2017-10-10 | 2017-10-10 | Anticorps multi-spécifique |
EP18150465 | 2018-01-05 | ||
EP18167093 | 2018-04-12 | ||
EP18180814 | 2018-06-29 | ||
PCT/EP2018/077509 WO2019072868A1 (fr) | 2017-10-10 | 2018-10-09 | Anticorps multispécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002982YA true SG11202002982YA (en) | 2020-04-29 |
Family
ID=63799025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002982YA SG11202002982YA (en) | 2017-10-10 | 2018-10-09 | Multispecific antibody |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230192897A1 (fr) |
EP (1) | EP3694873A1 (fr) |
JP (1) | JP7442443B2 (fr) |
KR (1) | KR20200063155A (fr) |
CN (1) | CN111194323B (fr) |
AU (1) | AU2018348429A1 (fr) |
BR (1) | BR112020006999A2 (fr) |
CA (1) | CA3075969A1 (fr) |
CL (2) | CL2020000937A1 (fr) |
CO (1) | CO2020003882A2 (fr) |
IL (1) | IL273576A (fr) |
MA (1) | MA50352A (fr) |
MX (1) | MX2020003562A (fr) |
SG (1) | SG11202002982YA (fr) |
WO (1) | WO2019072868A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific molecules that bind CD137 and cancer antigens and their uses |
US11578133B2 (en) * | 2017-10-10 | 2023-02-14 | Namab Therapeutics AG | Antibodies targeting CD137 and methods of use thereof |
EP3710477A1 (fr) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Anticorps à domaine unique qui se lient à cd137 |
WO2021013142A1 (fr) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et anticorps bispécifique |
US11466086B2 (en) | 2019-10-11 | 2022-10-11 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1BB and uses thereof |
EP3816185A1 (fr) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur |
KR20220107251A (ko) * | 2020-01-09 | 2022-08-02 | 에프. 호프만-라 로슈 아게 | 새로운 4-1bbl 삼량체-함유 항원 결합 분자 |
CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
EP3988568A1 (fr) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Traitement combiné |
WO2022136693A1 (fr) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite |
EP4373848A2 (fr) | 2021-07-22 | 2024-05-29 | University of Dundee | Mutéines thérapeutiques |
WO2023214047A1 (fr) | 2022-05-06 | 2023-11-09 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite |
EP4273162A1 (fr) | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0571613B1 (fr) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Materiels et methodes pour preparer des domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
DE60030323T2 (de) | 1999-12-24 | 2007-10-11 | Genentech, Inc., South San Francisco | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
CA2490009A1 (fr) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Ligands propres a un cible et associes a une proteine serique et procede d'identification correspondant |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2502413A1 (fr) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice |
JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
KR20070094909A (ko) | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
PL3241842T3 (pl) | 2007-06-26 | 2024-06-10 | F-Star Therapeutics Limited | Prezentacja środków wiążących |
ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
DK2334705T3 (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
EP4169951A1 (fr) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
AU2010272590B2 (en) | 2009-07-16 | 2013-10-10 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
EP2614082B1 (fr) | 2010-09-09 | 2018-10-03 | Pfizer Inc | Molécules de liaison 4-1bb |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
BR112017011092A2 (pt) * | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
AU2016219772A1 (en) * | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
CA2978942A1 (fr) * | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation |
JP6839101B2 (ja) | 2015-06-15 | 2021-03-03 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ヘテロ二量体多重特異性抗体フォーマット |
WO2017102835A1 (fr) * | 2015-12-14 | 2017-06-22 | Complix Nv | Molécule de liaison comprenant un polypeptide-alphacorps et un anticorps |
SG10201912405TA (en) * | 2016-01-11 | 2020-02-27 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
SG11202001654TA (en) * | 2017-10-10 | 2020-03-30 | Numab Therapeutics AG | Antibodies targeting pdl1 and methods of use thereof |
US11578133B2 (en) * | 2017-10-10 | 2023-02-14 | Namab Therapeutics AG | Antibodies targeting CD137 and methods of use thereof |
-
2018
- 2018-10-09 CA CA3075969A patent/CA3075969A1/fr active Pending
- 2018-10-09 WO PCT/EP2018/077509 patent/WO2019072868A1/fr unknown
- 2018-10-09 BR BR112020006999-0A patent/BR112020006999A2/pt unknown
- 2018-10-09 KR KR1020207010048A patent/KR20200063155A/ko not_active Application Discontinuation
- 2018-10-09 US US16/754,604 patent/US20230192897A1/en active Pending
- 2018-10-09 SG SG11202002982YA patent/SG11202002982YA/en unknown
- 2018-10-09 CN CN201880065327.3A patent/CN111194323B/zh active Active
- 2018-10-09 MA MA050352A patent/MA50352A/fr unknown
- 2018-10-09 AU AU2018348429A patent/AU2018348429A1/en active Pending
- 2018-10-09 JP JP2020519761A patent/JP7442443B2/ja active Active
- 2018-10-09 EP EP18783483.3A patent/EP3694873A1/fr active Pending
- 2018-10-09 MX MX2020003562A patent/MX2020003562A/es unknown
-
2020
- 2020-03-24 IL IL273576A patent/IL273576A/en unknown
- 2020-03-30 CO CONC2020/0003882A patent/CO2020003882A2/es unknown
- 2020-04-07 CL CL2020000937A patent/CL2020000937A1/es unknown
-
2021
- 2021-01-06 CL CL2021000028A patent/CL2021000028A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3694873A1 (fr) | 2020-08-19 |
JP2021501744A (ja) | 2021-01-21 |
CN111194323B (zh) | 2024-07-09 |
KR20200063155A (ko) | 2020-06-04 |
CL2021000028A1 (es) | 2021-05-28 |
MX2020003562A (es) | 2020-10-01 |
WO2019072868A1 (fr) | 2019-04-18 |
AU2018348429A1 (en) | 2020-03-12 |
JP7442443B2 (ja) | 2024-03-04 |
MA50352A (fr) | 2020-08-19 |
CA3075969A1 (fr) | 2019-04-18 |
CL2020000937A1 (es) | 2020-09-25 |
IL273576A (en) | 2020-05-31 |
CO2020003882A2 (es) | 2020-05-29 |
CN111194323A (zh) | 2020-05-22 |
BR112020006999A2 (pt) | 2020-10-06 |
US20230192897A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257760A1 (zh) | 多特異性抗體 | |
HK1254310A1 (zh) | 抗garp抗體 | |
IL267797A (en) | Anti-gpc3 antibody | |
IL273576A (en) | Antibody for multiple individuals | |
GB201621439D0 (en) | IL-11Ra Antibodies | |
GB201601073D0 (en) | Antibodies | |
IL256099A (en) | antibody | |
IL268889A (en) | Anti-EPHA4 antibody | |
GB201610044D0 (en) | Antibodies | |
GB201603291D0 (en) | Antibodies | |
GB201515351D0 (en) | Antibody | |
ZA201906981B (en) | Stable multispecific antibodies | |
HK1249549A1 (zh) | 抗體 | |
HUE057499T2 (hu) | Antitest | |
GB201600871D0 (en) | Antibody | |
IL273529A (en) | Anti-PACAP antibody | |
GB201616699D0 (en) | Antibodies | |
GB201612337D0 (en) | Ant-il-22r antibodies | |
GB201709592D0 (en) | Antibody | |
GB201620414D0 (en) | Antibodies | |
GB201615224D0 (en) | Antibodies | |
GB201613158D0 (en) | Antibodies | |
GB201612437D0 (en) | Anti-lag-3 antibodies | |
GB201513447D0 (en) | Antibody |